DNLI — Denali Therapeutics Share Price
0.000.00%
Last trade - 00:00- $2.54bn
- $1.51bn
- $330.53m
- 56
- 23
- 53
- 40
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.46 | ||
| Price to Tang. Book | 2.46 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.69 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -18.28% | ||
| Return on Equity | -14.01% | ||
| Operating Margin | -59.51% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 26.68 | 335.66 | 48.66 | 108.46 | 330.53 | 65.75 | 123.99 | 20.67% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
Directors
- Vicki Sato NEC (72)
- Ryan Watts PRE (45)
- Steve Krognes CFO (52)
- Alexander Schuth COO (47)
- Carole Ho OTH (48)
- Katie Peng OTH
- Erik Harris DRC (51)
- Douglas Cole IND (60)
- Jennifer Cook IND (55)
- Jay Flatley IND (69)
- Peter Klein IND (59)
- Robert Nelsen IND (58)
- David Schenkein IND (63)
- Marc Tessier-Lavignec IND (61)
- Nancy Thornberry IND (64)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 14th, 2013
- Public Since
- December 8th, 2017
- No. of Shareholders
- 144
- No. of Employees
- 445
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 139,160,239
- Address
- 161 Oyster Point Blvd, SOUTH SAN FRANCISCO, 94080-1910
- Web
- https://www.denalitherapeutics.com
- Phone
- +1 6508668548
- Auditors
- Ernst & Young LLP
Upcoming Events for DNLI
Denali Therapeutics Inc Annual Shareholders Meeting
Q2 2024 Denali Therapeutics Inc Earnings Release
Similar to DNLI
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Denali Therapeutics share price?
As of Today at 19:06 UTC, shares in Denali Therapeutics are trading at $18.26. This share price information is delayed by 15 minutes.
How has the Denali Therapeutics share price performed this year?
Shares in Denali Therapeutics last closed at $18.26 and the price had moved by -26.19% over the past 365 days. In terms of relative price strength the Denali Therapeutics share price has underperformed the S&P500 Index by -40.39% over the past year.
What are the analyst and broker recommendations for Denali Therapeutics?
The overall consensus recommendation for Denali Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Denali Therapeutics dividend yield?
Denali Therapeutics does not currently pay a dividend.
Does Denali Therapeutics pay a dividend?
Denali Therapeutics does not currently pay a dividend.
When does Denali Therapeutics next pay dividends?
Denali Therapeutics does not currently pay a dividend.
How do I buy Denali Therapeutics shares?
To buy shares in Denali Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Denali Therapeutics?
As of the previous close price of $18.26, shares in Denali Therapeutics had a market capitalisation of $2.54bn.
Where are Denali Therapeutics shares listed?
Here are the trading details for Denali Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: DNLI
What kind of share is Denali Therapeutics?
Based on an overall assessment of its quality, value and momentum Denali Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Denali Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Denali Therapeutics is $41.19. That is 125.58% above the last closing price of $18.26.
Analysts covering Denali Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.64 for the next financial year.
What is the trend in the Denali Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Denali Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -24.91%.
As of the last closing price of $18.26, shares in Denali Therapeutics were trading -14.53% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Denali Therapeutics PE Ratio?
The Denali Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $18.26.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Denali Therapeutics?
Denali Therapeutics' management team is headed by:
- Vicki Sato - NEC
- Ryan Watts - PRE
- Steve Krognes - CFO
- Alexander Schuth - COO
- Carole Ho - OTH
- Katie Peng - OTH
- Erik Harris - DRC
- Douglas Cole - IND
- Jennifer Cook - IND
- Jay Flatley - IND
- Peter Klein - IND
- Robert Nelsen - IND
- David Schenkein - IND
- Marc Tessier-Lavignec - IND
- Nancy Thornberry - IND